AcuraBio (formerly Luina Bio), an Australian biopharmaceutical CDMO, has been acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, a global healthcare private equity firm.
 
With more than two decades of experience, AcuraBio is a globally focused organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries. AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers developing emerging therapeutics.
 
The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr. Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organization to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities.
 
Dr. Haifer brings a wealth of experience to AcuraBio, as the former company Chairman and investor behind Australian biotech successes such as Agilex Biolabs and Avance Clinical. “We are very excited to be reinventing a company with such deep scientific experience,” said Dr. Haifer. “With our deep expertise and commitment to further investment, AcuraBio will be a leader in the APAC region for international biopharma clients attracted by the technology, scientific excellence, and innovation we will bring to the platform. I am excited to leverage Ampersand’s industry expertise as we take AcuraBio to the next level.”